Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(30 sites)
United States
University of Alabama at Birmingham, Birmingham, Alabama Mayo Clinic-AZ, Phoenix, Arizona City of Hope, Duarte, California University of California-Los Angeles, Los Angeles, California University of California-San Francisco, San Francisco, California University of Colorado Denver, Aurora, Colorado Mayo Clinic-Jacksonville, Jacksonville, Florida University of Miami, Miami, Florida Moffit Cancer Center, Tampa, Florida Emory University, Atlanta, Georgia Northwestern University Medical Hospital, Chicago, Illinois John Hopkins Cancer Center, Baltimore, Maryland Massachusetts General Hospital, Boston, Massachusetts Dana Farber Cancer Institute, Boston, Massachusetts Karmanos Cancer Center, Detroit, Michigan Washington University, St Louis, Missouri Memorial Sloan Kettering Cancer Center, New York, New York Cornell Cancer Center, New York, New York Duke Cancer Center, Durham, North Carolina Cleveland Clinic, Cleveland, Ohio Ohio State University, Columbus, Ohio Oregon Health and Science University, Portland, Oregon Medical University of South Carolina, Charleston, South Carolina Sarah Cannon Research Institute, Nashville, Tennessee UT Southwestern Medical Center, Dallas, Texas MD Anderson Cancer Center, Houston, Texas France
Hopital La Timone, Marseille Hopital Haut-Leveque, Pessac Central Lyon Sud, Pierre-Bénite Institute Gustave Roussly (IGR), Villejuif